PortfoliosLab logo
Merus N.V. (MRUS)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

NL0011606264

IPO Date

May 19, 2016

Highlights

Market Cap

$2.83B

EPS (TTM)

-$3.35

Total Revenue (TTM)

$37.38M

Gross Profit (TTM)

$37.38M

EBITDA (TTM)

-$331.91M

Year Range

$33.19 - $61.61

Target Price

$84.07

Short %

9.13%

Short Ratio

7.58

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Performance

Performance Chart


Loading data...

Returns By Period

Merus N.V. (MRUS) returned -2.73% year-to-date (YTD) and -8.13% over the past 12 months.


MRUS

YTD

-2.73%

1M

5.90%

6M

-24.95%

1Y

-8.13%

5Y*

20.72%

10Y*

N/A

^GSPC (Benchmark)

YTD

-3.77%

1M

7.44%

6M

-5.60%

1Y

8.37%

5Y*

14.12%

10Y*

10.46%

*Annualized

Monthly Returns

The table below presents the monthly returns of MRUS, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2025-2.64%15.02%-10.62%8.13%-10.13%-2.73%
202429.75%35.87%-7.12%-0.27%18.55%11.14%-10.36%-3.87%-2.02%-0.06%-10.19%-6.22%52.91%
20230.84%22.24%-3.51%4.24%13.24%21.22%-0.34%-14.75%5.41%-14.72%23.02%11.16%77.76%
2022-22.61%14.14%-5.87%-22.84%-9.02%21.98%6.80%-2.07%-15.41%2.35%-25.12%0.78%-51.35%
202156.99%-18.24%-7.16%0.24%1.00%-0.38%-18.37%51.63%-15.64%27.50%-7.27%22.26%81.40%
202016.12%3.36%-28.40%22.64%-8.02%17.88%-14.92%-11.83%-0.58%1.50%40.64%2.34%24.50%
2019-13.50%-3.55%26.46%4.54%-9.97%5.40%7.51%1.59%11.37%-12.12%5.24%-14.56%0.57%
2018-4.23%-5.76%5.83%-2.91%3.95%21.71%-1.80%-4.12%-7.89%-24.01%-17.27%12.81%-27.84%
201723.69%-6.13%-0.49%-8.98%-12.79%-18.13%3.28%-11.12%36.56%-20.43%11.26%10.29%-8.10%
2016-14.24%-7.20%31.91%-13.66%84.07%6.27%-14.80%39.19%110.26%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of MRUS is 36, indicating average performance compared to other stocks on our website. Here’s a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of MRUS is 3636
Overall Rank
The Sharpe Ratio Rank of MRUS is 4444
Sharpe Ratio Rank
The Sortino Ratio Rank of MRUS is 3636
Sortino Ratio Rank
The Omega Ratio Rank of MRUS is 3636
Omega Ratio Rank
The Calmar Ratio Rank of MRUS is 2727
Calmar Ratio Rank
The Martin Ratio Rank of MRUS is 3535
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Merus N.V. (MRUS) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.

Merus N.V. Sharpe ratios as of May 11, 2025 (values are recalculated daily):

  • 1-Year: -0.16
  • 5-Year: 0.33
  • All Time: 0.25

These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns (including price changes and dividends).

The chart below shows the rolling Sharpe ratio of Merus N.V. compared to the selected benchmark. This view highlights how the investment's risk-adjusted performance has changed over time. For deeper analysis or to customize the calculation, use the Sharpe ratio tool.


Loading data...

Dividends

Dividend History


Merus N.V. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


Loading data...

Worst Drawdowns

The table below displays the maximum drawdowns of the Merus N.V.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Merus N.V. was 67.42%, occurring on Apr 3, 2020. Recovery took 435 trading sessions.

The current Merus N.V. drawdown is 32.06%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-67.42%Mar 7, 2017776Apr 3, 2020435Dec 23, 20211211
-60.36%Dec 31, 2021244Dec 19, 2022263Jan 8, 2024507
-42.04%Jun 28, 2024195Apr 8, 2025
-26.33%Oct 25, 201633Dec 16, 20163Dec 21, 201636
-25.44%May 26, 20162May 27, 201643Jul 29, 201645

Volatility

Volatility Chart

The chart below shows the rolling one-month volatility.


Loading data...

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Merus N.V. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Earnings Per Share

The chart presents the Earnings Per Share (EPS) performance of Merus N.V., comparing actual results with analytics estimates. In the past quarter, the company did not meet analyst expectations for EPS, resulting in a surprise of -31.6%.


-2.00-1.50-1.00-0.500.0020212022202320242025
-1.40
-1.06
Actual
Estimate

Valuation

The Valuation section provides an overview of how Merus N.V. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PEG Ratio

The chart shows the Price/Earnings to Growth (PEG) ratio for MRUS compared to other companies in the Biotechnology industry. MRUS currently has a PEG ratio of 0.0. This PEG ratio is low compared to industry peers, which could indicate the stock is undervalued relative to its expected growth.

PS Ratio

This chart shows the Price-to-Sales (P/S) ratio for MRUS relative to other companies in the Biotechnology industry. Currently, MRUS has a P/S ratio of 78.3. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.

PB Ratio

The chart illustrates the Price-to-Book (P/B) ratio for MRUS in comparison with other companies in the Biotechnology industry. Currently, MRUS has a P/B value of 4.4. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items